Vimarsana
Biggest News Aggregation in the World

Intelligent Bio Sys News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Intelligent Bio Sys. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Intelligent Bio Sys Today - Breaking & Trending Today

Trending At The PTAB: Permissible New Reply Arguments - Patent - Vimarsana News

Trending At The PTAB: Permissible New Reply Arguments - Patent

In inter partes review proceedings, the Patent Trial and Appeal Board has historically been reticent to consider arguments raised for the first time in a petitioner's reply.

Source: mondaq.com
Replies in Inter Partes Review – How Far is Too Far? | Kilpatrick Townsend & Stockton LLP - Vimarsana News

Replies in Inter Partes Review – How Far is Too Far? | Kilpatrick Townsend & Stockton LLP

Parties in inter partes review proceedings often dispute whether a reply to a patent owner response is truly responsive or instead an attempt to introduce new arguments that are not...

Replies in Inter Partes Review - How Far is Too Far? - Vimarsana News

Replies in Inter Partes Review - How Far is Too Far?

Parties in inter partes review proceedings often dispute whether a reply to a patent owner response is truly responsive or instead an attempt to…

Rembrandt Diagnostics LP v. Alere, Inc. (Fed. Cir. 2023) | McDonnell Boehnen Hulbert & Berghoff LLP - Vimarsana News

Rembrandt Diagnostics LP v. Alere, Inc. (Fed. Cir. 2023) | McDonnell Boehnen Hulbert & Berghoff LLP

The Federal Circuit reviewed the latest decision from the Patent Trial and Appeal Board (PTAB) in an inter partes review that claims 3-6 and 10 of U.S. Patent No. 6,548,019 are obvious,...

Failure To Show A Reasonable Expectation Of Success Dooms Obviousness Allegations - Intellectual Property - Vimarsana News

Failure To Show A Reasonable Expectation Of Success Dooms Obviousness Allegations - Intellectual Property

In Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc., the Federal Circuit affirmed the obviousness analysis performed by the Patent Trial and Appeal Board ("PTAB"),...

Source: mondaq.com